Journal article

Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial

Abstract:: Background: Infants in the UK were first offered a pneumococcal conjugate vaccine (PCV7) in 2006, given at 2 and 4 months of age and a booster dose at 13 months (2 + 1 schedule). A 13-valent vaccine (PCV13) replaced PCV7 in 2010. We aimed to compare the post-booster antibody response in UK infants given a reduced priming schedule of PCV13 (ie, a 1 + 1 schedule) versus the current 2 + 1 schedule and to assess the potential effect on population protection.

Methods: In t...
Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Goldblatt, D., Southern, J., Andrews, N., Burbidge, P., Partington, J., Roalfe, L., Valente Pinto, M., Thalasselis, V., Plested, E., Richardson, H., Snape, M., & Miller, E. (2017). Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial. Lancet Infectious Diseases, 18(2), 171–179.

MLA Style

Goldblatt, D., et al. “Pneumococcal Conjugate Vaccine 13 Delivered as One Primary and One Booster Dose (1 + 1) Compared with Two Primary Doses and a Booster (2 + 1) in UK Infants: a Multicentre, Parallel Group Randomised Controlled Trial.” Lancet Infectious Diseases, vol. 18, no. 2, Lancet, 2017, pp. 171–79.

Chicago Style

Goldblatt, D, J Southern, N Andrews, P Burbidge, J Partington, L Roalfe, M Valente Pinto, et al. 2017. “Pneumococcal Conjugate Vaccine 13 Delivered as One Primary and One Booster Dose (1 + 1) Compared with Two Primary Doses and a Booster (2 + 1) in UK Infants: a Multicentre, Parallel Group Randomised Controlled Trial.” Lancet Infectious Diseases 18 (2): 171–79.
Share
Print

Access Document

Files:: Pneumococcal conjugate vaccine 13.pdf

(Preview, Version of record, pdf, 189.2KB, Terms of use)

Publisher copy:: 10.1016/s1473-3099(17)30654-0

Authors

+ Goldblatt, D More by this author

Role:: Author

+ Southern, J More by this author

Role:: Author

+ Andrews, N More by this author

Role:: Author

+ Burbidge, P More by this author

Role:: Author

+ Partington, J More by this author

Institution:: University of Oxford
Division:: Medical Sciences Division
Department:: Paediatrics
Role:: Author

More authors...

+ Bill and Melinda Gates Foundation More from this funder

Grant:: OPP1126431

+ National Institute for Health Research More from this funder

Grant:: 039/0031

Publisher:: Lancet
Journal:: Lancet Infectious Diseases More from this journal
Volume:: 18
Issue:: 2
Pages:: 171-179
Publication date:: 2017-11-22
Acceptance date:: 2017-11-01
DOI:: 10.1016/s1473-3099(17)30654-0
EISSN:: 1474-4457
ISSN:: 1473-3099
Pmid:: 29174323

Language:: English
Keywords:: Journal Article
Pubs id:: pubs:808713
UUID:: uuid:e5ad46c3-7eb7-4d09-a468-5b90872900c5
Local pid:: pubs:808713
Source identifiers:: 808713
Deposit date:: 2018-01-05

Terms of use

Copyright holder:: Goldblatt et al
Copyright date:: 2017
Notes:: © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Licence:: CC Attribution (CC BY)

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP